ERBB2 and colorectal carcinoma: The baseline assessment embedded within “GetSMART” confirmed the findings of the survey, appropriately addressing identified knowledge and confidence gaps related to the (1) identification of HER2 aberrations, (2) selection of appropriate treatments for HER2+ G&CRC, and (3) patient engagement in SDM and management of AEs.